CD19 抗体 (AA 96-281)
-
- 抗原 See all CD19 抗体
- CD19 (CD19 Molecule (CD19))
-
抗原表位
- AA 96-281
-
适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This CD19 antibody is un-conjugated
-
应用范围
- Flow Cytometry (FACS), Immunohistochemistry (IHC), ELISA, Coating (Coat), Staining Methods (StM)
- 纯化方法
- Purified by Protein A/G
- 免疫原
- Recombinant fragment of human CD19 protein (around aa96-281) (exact sequence is proprietary)
- 克隆位点
- CD19-3117
- 亚型
- IgG2b kappa
- Top Product
- Discover our top product CD19 Primary Antibody
-
-
- 应用备注
-
Positive Control: Raji cells (FACS). Tonsil, Lymph Node or Spleen (IHC).
Known Application: ELISA (For coating, order antibody without BSA), ,Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT),(Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined.
- 限制
- 仅限研究用
-
- 浓度
- 200 μg/mL
- 缓冲液
- 10 mM PBS with 0.05 % BSA & 0.05 % azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C,-80 °C
- 储存方法
- Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
- 有效期
- 24 months
-
- 抗原
- CD19 (CD19 Molecule (CD19))
- 别名
- CD19 (CD19 产品)
- 别名
- B4 antibody, CVID3 antibody, AW495831 antibody, CD19 antibody, CD19 molecule antibody, CD19 antigen antibody, CD19 antibody, Cd19 antibody
- 背景
- CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.
- 分子量
- 95kDa
- 基因ID
- 930
- UniProt
- P15391
- 途径
- Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway
-